Literature DB >> 26763865

Characteristics of non-obese non-alcoholic fatty liver disease: Effect of genetic and environmental factors.

Yasushi Honda1, Masato Yoneda1, Takaomi Kessoku1, Yuji Ogawa1, Wataru Tomeno1, Kento Imajo1, Hironori Mawatari1, Koji Fujita1, Hideyuki Hyogo2, Takato Ueno3, Kazuaki Chayama4, Satoru Saito1, Atsushi Nakajima1, Kikuko Hotta5.   

Abstract

AIM: There are a considerable number of patients with non-obese non-alcoholic fatty liver disease (NAFLD). However, the clinical characteristics of non-obese NAFLD is not fully understood. We investigated genetic and other clinical parameters in non-obese and obese NAFLD.
METHODS: The single nucleotide polymorphism rs738409 in the patatin-like phospholipase 3 gene (PNPLA3) was genotyped by the Invader assay in 540 NAFLD patients (134 non-obese and 406 obese) and 1012 control subjects (782 non-obese and 230 obese). All NAFLD patients underwent liver biopsy. Odds ratios were calculated by multiple logistic regression analysis using age, sex, body mass index (BMI), type 2 diabetes mellitus (T2DM) and rs738409 genotype as explanatory variables.
RESULTS: Non-obese NAFLD subjects had a higher rs738409 GG genotype than obese NAFLD. Multiple logistic regression analysis indicated that the odds ratios of T2DM and rs738409 GG genotype for NAFLD were higher in non-obese than in obese groups. In non-obese NAFLD, rs738409 GG genotype was associated with lobular inflammation, hepatocyte ballooning and NAFLD activity score. In obese NAFLD, BMI and T2DM but not rs738409 GG genotype were associated with severity of histology.
CONCLUSION: We demonstrated that the risk factors for the development and progression of NAFLD were different between non-obese and obese patients and that PNPLA3 rs738409 was strongly associated with the development and progression of non-obese NAFLD.
© 2016 The Japan Society of Hepatology.

Entities:  

Keywords:  PNPLA3; non-alcoholic fatty liver disease; non-obese non-alcoholic fatty liver disease; type 2 diabetes mellitus

Year:  2016        PMID: 26763865     DOI: 10.1111/hepr.12648

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  22 in total

Review 1.  NAFLD and HIV: Do Sex, Race, and Ethnicity Explain HIV-Related Risk?

Authors:  Subada Soti; Kathleen E Corey; Jordan E Lake; Kristine M Erlandson
Journal:  Curr HIV/AIDS Rep       Date:  2018-06       Impact factor: 5.071

2.  The metabolic profiles and body composition of lean metabolic associated fatty liver disease.

Authors:  Yu-Ming Cheng; Jia-Horng Kao; Chia-Chi Wang
Journal:  Hepatol Int       Date:  2021-02-04       Impact factor: 6.047

3.  Associations of body shape index (ABSI) and hip index with liver, metabolic, and inflammatory biomarkers in the UK Biobank cohort.

Authors:  Sofia Christakoudi; Elio Riboli; Evangelos Evangelou; Konstantinos K Tsilidis
Journal:  Sci Rep       Date:  2022-05-25       Impact factor: 4.996

4.  Comparison of long-term prognosis between non-obese and obese patients with non-alcoholic fatty liver disease.

Authors:  Michihiro Iwaki; Takaomi Kessoku; Kosuke Tanaka; Anna Ozaki; Yuki Kasai; Atsushi Yamamoto; Kota Takahashi; Takashi Kobayashi; Asako Nogami; Yasushi Honda; Yuji Ogawa; Kento Imajo; Shunsuke Oyamada; Noritoshi Kobayashi; Shinichi Aishima; Satoru Saito; Atsushi Nakajima; Masato Yoneda
Journal:  JGH Open       Date:  2022-08-24

5.  Non-obese histologically confirmed NASH patients with abnormal liver biochemistry have more advanced fibrosis.

Authors:  Qianyi Wang; Hong You; Xiaojuan Ou; Xinyan Zhao; Yameng Sun; Min Wang; Ping Wang; Yu Wang; Weijia Duan; Xiaoming Wang; Shanshan Wu; Yuanyuan Kong; Romil Saxena; Annette S H Gouw; Jidong Jia
Journal:  Hepatol Int       Date:  2019-09-26       Impact factor: 6.047

6.  Association between body size-metabolic phenotype and nonalcoholic steatohepatitis and significant fibrosis.

Authors:  Donghee Kim; Won Kim; Sae Kyung Joo; Jimin Han; Jung Ho Kim; Stephen A Harrison; Zobair M Younossi; Aijaz Ahmed
Journal:  J Gastroenterol       Date:  2019-09-18       Impact factor: 7.527

7.  Evaluation of the Impact of Metabolic Syndrome on Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease.

Authors:  Haluk Tarik Kani; Coskun Ozer Demirtas; Caglayan Keklikkiran; Ilkay Ergenc; Shahin Mehdiyev; Esra Akdeniz; Yusuf Yilmaz
Journal:  Turk J Gastroenterol       Date:  2021-08       Impact factor: 1.852

Review 8.  Emerging Role of Genomic Analysis in Clinical Evaluation of Lean Individuals With NAFLD.

Authors:  Sílvia Vilarinho; Veeral Ajmera; Melanie Zheng; Rohit Loomba
Journal:  Hepatology       Date:  2021-10       Impact factor: 17.298

Review 9.  Lean NAFLD: an underrecognized and challenging disorder in medicine.

Authors:  Sheila Maier; Amanda Wieland; Melanie Cree-Green; Kristen Nadeau; Shelby Sullivan; Miguel A Lanaspa; Richard J Johnson; Thomas Jensen
Journal:  Rev Endocr Metab Disord       Date:  2021-01-03       Impact factor: 6.514

10.  Association between PNPLA3 rs738409 polymorphism and nonalcoholic fatty liver disease: a systematic review and meta-analysis.

Authors:  Nader Salari; Niloufar Darvishi; Kamran Mansouri; Hooman Ghasemi; Melika Hosseinian-Far; Fateme Darvishi; Masoud Mohammadi
Journal:  BMC Endocr Disord       Date:  2021-06-19       Impact factor: 2.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.